Discover the science behind abrocitinib, a JAK-1 selective inhibitor approved for treating moderate-to-severe atopic dermatitis (AD). This showcase features a collated collection of published manuscripts, plain language summaries, video abstracts and congress presentations related to abrocitinib.
Stay tuned - more insights and resources will be added over time.
